The unique ability of dendritic cells to pick up antigens and to activate naive and memory CD4+ and CD8+ T cells raised the possibility of using them to trigger a specific anti-tumor immunity. If numerous studies have shown a major interest in dendritic cell-based vaccines for cancer immunotherapy in animal models, only a few have been carried out in human cancers. In this review, we describe recent findings in the biology of dendritic cells that are important to generate anti-tumor cytotoxic T cells in vitro and we also detail clinical studies reporting the obtention of specific immunity to human cancers in vivo using reinfusion of dendritic cells pulsed with tumor antigens.
展开▼
机译:树突状细胞吸收抗原并激活幼稚和记忆 CD4+ 和 CD8+ T 细胞的独特能力提高了使用它们触发特异性抗肿瘤免疫的可能性。如果许多研究表明,在动物模型中对基于树突状细胞的疫苗进行癌症免疫治疗产生了浓厚的兴趣,那么只有少数研究在人类癌症中进行了研究。在这篇综述中,我们描述了树突状细胞生物学的最新发现,这些发现对于在体外产生抗肿瘤细胞毒性T细胞很重要,我们还详细介绍了临床研究报告,使用用肿瘤抗原脉冲的树突状细胞在体内获得对人类癌症的特异性免疫。
展开▼